Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial (Q34373867)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial (English)

1 reference

Europe PubMed Central

1 August 2017

anti-retroviral agent

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

Eugenia Quiros-Roldan

3

object named as

Eugenia Quiros-Roldan

0 references

7

object named as

Jean-Guy Baril

1 reference

Europe PubMed Central

1 August 2017

François Raffi

1

object named as

François Raffi

1 reference

Europe PubMed Central

1 August 2017

author name string

Hans Jaeger

2

1 reference

Europe PubMed Central

1 August 2017

Helmut Albrecht

4

1 reference

Europe PubMed Central

1 August 2017

Elena Belonosova

5

1 reference

Europe PubMed Central

1 August 2017

Jose M Gatell

6

1 reference

Europe PubMed Central

1 August 2017

Pere Domingo

8

1 reference

Europe PubMed Central

1 August 2017

Clare Brennan

9

1 reference

Europe PubMed Central

1 August 2017

Steve Almond

10

1 reference

Europe PubMed Central

1 August 2017

Sherene Min

11

1 reference

Europe PubMed Central

1 August 2017

extended SPRING-2 Study Group

12

1 reference

Europe PubMed Central

1 August 2017

publication date

25 September 2013

1 reference

Europe PubMed Central

1 August 2017

Lancet Infectious Diseases

1 reference

Europe PubMed Central

1 August 2017

13

1 reference

Europe PubMed Central

1 August 2017

11

1 reference

Europe PubMed Central

1 August 2017

927-935

1 reference

Europe PubMed Central

1 August 2017

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Quad's in it for antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrase inhibitors in the treatment of HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Designing and interpreting HIV noninferiority trials in naive and experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of trimethoprim on serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970257-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(13)70257-3

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34373867&oldid=1986236029"